hyperphosphataemia in chronic kidney disease
Endocrinology · 2006–2019
10decisions
4medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sevelamer carbonate Management of hyperphosphataemia in patients with chronic kidney disease that require dialysis. | Mar 2019 | Recommended | no section in document |
| sevelamer carbonate Hyperphosphataemia in patients undergoing dialysis for chronic kidney disease (stage 4 and 5 CKD). | Nov 2017 | Recommended with restriction | none received |
| sucroferric oxyhydroxide Treatment of hyperphosphataemia in patients undergoing dialysis for chronic kidney disease. | Jul 2015 | Recommended with restriction | no section in document |
| sucroferric oxyhydroxide Hyperphosphataemia in patients with chronic kidney disease on dialysis. Treatment is for patients uncontrolled on calcium-based phosphate binders, as an… | Nov 2014 | Recommended with restriction | input received |
| lanthanum carbonate hydrate Management and maintenance of hyperphosphataemia in patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products… | Nov 2008 | Recommended with restriction | no section in document |
| sevelamer hydrochloride Treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products. | Jul 2007 | Recommended with restriction | no section in document |
| lanthanum carbonate hydrate Treatment of hyperphosphataemia in adult patients with chronic renal failure on dialysis whose serum calcium levels are at least 2.60 mmol/L. | Mar 2007 | Not recommended | no section in document |
| sevelamer hydrochloride Treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products. | Mar 2006 | Recommended | no section in document |
| sevelamer hydrochloride Treatment of hyperphosphataemia in adult patients with chronic kidney disease on dialysis whose serum phosphate is not controlled on other products. | Mar 2006 | Recommended | no section in document |
| sevelamer hydrochloride Treatment of high phosphate levels (hyperphosphataemia) in adult patients with chronic kidney disease on dialysis. | Nov 2006 | Not recommended | no section in document |
What the PBS pays
$35M in government benefit over 2024–25, across 143,010 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| sevelamer | $9.8M |
| sevelamer carbonate | $9.8M |
| sevelamer hydrochloride | $9.8M |
| lanthanum carbonate | $4.1M |
| sucroferric oxyhydroxide | $1.5M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.